-
Orforglipron (CAS: 2212020-52-3)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Orforglipron Type 2 Diabetes Eli Lilly and Company Sep.26,2037 -
Osimertinib (CAS: 1421373-65-0)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Osimertinib NSCLC AstraZeneca Aug.8,2032 -
Oteseconazole (CAS: 1340593-59-0)
API’s Name Indication Innovator Patent Expiry Date(The U.S) Oteseconazole Reduce the incidence rate ofrecurrent vulvovaginal candidiasis MycoviaPharmaceuticals Apr.22,2031 -
Obeticholic Acid
API’s Name Indication Specification US DMF EU DMF CEP Obeticholic Acid Biliary cholangitis In-House